Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases in the areas of various orphan and niche indications in North America and the EU. The company offers Raxone/Catena for the treatment of Friedreich’s Ataxia. Its products under development include Raxone/Catena, which is in preparation for regulatory re-submission marketing authorization in Europe for Leber's Hereditary Optic Neuropathy, in a Phase III study for Duchenne Muscular Dystrophy, and in a Phase II study for Primary Progressive Multiple Sclerosis; omigapil that is in Phase I pharmacokinetics study in pediatric patients with Congenital Muscular Dystrophy; and Fipamezole, which has completed Phase IIb study for treatment of Dyskinesia in Parkinson's disease. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Liestal, Switzerland.
(SANN:SIX Swiss Ex)
Phone: 41 61 906 89 50
Fax: 41 61 906 89 51www.santhera.com
|No competitor information is available for SANN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact SANTHERA PHARMACEUTICALS-REG, please visit www.santhera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.